Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Allarity Therapeutics, Inc.ALLR · healthcare
GradeNonecomputable_factors_below_threshold: 5 of 14 inputs computable; 7 are required
Reliability0.83 AUCfailure model, filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate1.07% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$12.5M to $120M assetstotal assets $18.3M[1]
Standard universeoutsiderevenue above $1M and assets above $10M[1-2]
Warningslate filer, thin datanot computable: distress, fortress balance sheet
Inputs computable5 of 14
Graded fromfilings received through Mar 30, 2026193 days before the rescan; every figure keyed to the SEC receipt date
Last close$1.002026-10-07; market equity $15.9M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$1$1.5NovDecJanFebMarAprMayJunJulAugSepOct$0.98
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
May 21, 2022nonen/aQ2
Mar 21, 2024nonen/aQ1
Apr 21, 2025nonen/aQ2

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 30, 2026; the document on sec.gov.

We are a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical need. We were founded on the innovation of our novel Drug Response Predictor (DRP®) platform. The DRP® technology is designed to define the gene expression signatures in cancer cells that predict the cancer cell’s sensitivity to a specific cancer therapeutic.

Warnings [top]

Late filer. found 1 NT 10-K/Q filings in the last eight quarters
Thin data. 5 of 14 grade factors are computable; minimum is 7

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 94.7
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
required facts have no common fiscal period end
Accruals ratio17.5%[1,3-5](6.6%)94.78112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 72.7
Twelve-month failure probabilitynot computable0.07%
latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime(23.25)[1,6-11](0.31)76.07562025-12-31
Net debt to EBITDAnot computable1.82x
required facts have no common fiscal period end
Interest coveragenot computable(4.51x)
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio2.13x[6-7]2.96x69.58392025-12-31
Growth and financing, sleeve percentile 18.4
Revenue growth, three-year compoundnot computable10.0%
four annual observations are required; found 1
Free cash flow growth, three-year compoundnot computable10.9%
four consecutive annual FCF observations are required; found 3
Reinvestment ratenot computable37.1%
NOPAT must exceed $100,000
Asset growth, three years7.9%[1,5,12-13]2.1%35.07042025-12-31
Net share issuance, one year(7.0%)[14-15]2.5%1.96342026-03-30

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-07 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month(10.8%)8.0%39hotter than 39 of 100 peers
Distance from 52-week high(44.5%)(31.4%)33closer to its high than 33 of 100 peers
EBIT to enterprise value(949.4%)(1.5%)2pricier than 98 of 100 peers
Free cash flow yield(94.9%)(1.0%)5pricier than 95 of 100 peers
Book value to price0.230.2844pricier than 56 of 100 peers
Sales to price0.020.319pricier than 91 of 100 peers
Composite equity issuance, five yearsnot computable20.3%a share count from five years earlier is required
Relative strength against the sector, log excess return(0.33)(0.14)39ahead of 39 of 100 peers

Inputs: market equity $15.6M; EBIT -$12.6M; free cash flow -$14.8M; book equity $3.5M; sales $320,000; debt $2.7M; cash $17.0M[16].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(49.6%)✗ fail[3,5]
Operating cash flow above zero-$14.8M✗ fail[4]
Return on assets improved157.1 pts✓ pass[3,5,12,17]
Operating cash flow exceeds net income-$3.6M✗ fail[3-4]
Long-term leverage felln/a[1,5,12]
Current ratio improved6.6 pts✓ pass[6-7,18-19]
No new shares issued(7.0%)✓ pass[14-15]
Gross margin improvedn/a
Asset turnover improvedn/a[2,5,12]
Cash, filings, liquidity
Cash and equivalents$17.0M[20]
Operating cash flow, four quarters-$13.7M[4,20-24]
Months of runway14.9
Late filings, two years1
NT 10-K or NT 10-Q
Days since last periodic filing56
10-Q received Aug 14, 2026
Median daily dollar volume$82,539
63 sessions
Days since newest grade input193

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$18.3M2025-12-312026-03-3010-Kfiling · viewer · series
2revenueus-gaap:RevenueFromContractWithCustomerIncludingAssessedTax$320,0002025-12-312026-03-3010-Kfiling · viewer · series
3net incomeus-gaap:NetIncomeLoss-$11.2M2025-12-312026-03-3010-Kfiling · viewer · series
4operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$14.8M2025-12-312026-03-3010-Kfiling · viewer · series
5assetsus-gaap:Assets$22.6M2024-12-312026-03-3010-Kfiling · viewer · series
6current assetsus-gaap:AssetsCurrent$17.9M2025-12-312026-03-3010-Kfiling · viewer · series
7current liabilitiesus-gaap:LiabilitiesCurrent$8.4M2025-12-312026-03-3010-Kfiling · viewer · series
8retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$130.2M2025-12-312026-03-3010-Kfiling · viewer · series
9operating incomeus-gaap:OperatingIncomeLoss-$12.6M2025-12-312026-03-3010-Kfiling · viewer · series
10book equityus-gaap:StockholdersEquity$9.8M2025-12-312026-03-3010-Kfiling · viewer · series
11liabilitiesus-gaap:Liabilities$8.4M2025-12-312026-03-3010-Kfiling · viewer · series
12assetsus-gaap:Assets$11.9M2023-12-312025-03-3110-Kfiling · viewer · series
13assetsus-gaap:Assets$14.5M2022-12-312024-03-0810-Kfiling · viewer · series
14shares outstandingdei:EntityCommonStockSharesOutstanding15,818,9802026-03-302026-03-3010-Kfiling · viewer · series
15shares outstandingdei:EntityCommonStockSharesOutstanding17,014,7372025-03-312025-03-3110-Kfiling · viewer · series
16shares outstandingdei:EntityCommonStockSharesOutstanding15,910,7242026-08-142026-08-1410-Qfiling · viewer · series
17net incomeus-gaap:NetIncomeLoss-$24.5M2024-12-312026-03-3010-Kfiling · viewer · series
18current assetsus-gaap:AssetsCurrent$22.3M2024-12-312026-03-3010-Kfiling · viewer · series
19current liabilitiesus-gaap:LiabilitiesCurrent$10.8M2024-12-312026-03-3010-Kfiling · viewer · series
20cashus-gaap:CashAndCashEquivalentsAtCarryingValue$17.0M2026-06-302026-08-1410-Qfiling · viewer · series
21operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$7.1M2026-06-302026-08-1410-Qfiling · viewer · series
22operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$4.5M2026-03-312026-05-1510-Qfiling · viewer · series
23operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$11.6M2025-09-302025-11-1410-Qfiling · viewer · series
24operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$8.2M2025-06-302026-08-1410-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.